Patients with type 2 diabetes are at increased risk of cardiovascular disease. Fibrate may help decrease the risk of cardiovascular disease in women and could be an option for patients who cannot tolerate statins.
Are you trying to be the “perfect” person with diabetes? If so, you could be setting yourself up to feel like a failure. Why? Because there is no such thing as the perfect person with diabetes. Setting a goal to have “perfect” blood glucose control is admirable, but the concept of “perfect” blood glucose control […]
Swedish researchers have found that insulin pump users have better medical outcomes than those who use multiple daily injections. Also in recent news, The Juvenile Diabetes Research Foundation has awarded a $500,000 grant for research on an implantable encapsulation device that releases insulin-producing beta cells in the bloodstream of people with Type 1 diabetes.
The biggest annual diabetes conference in Europe took place last week – the European Association for the Study of Diabetes (EASD) — bringing thousands from the D-field this year to Austria, for what many of us in the States refer to as “Europe’s version of the annual ADA Meeting.”
Updates on the European Approval to Launch the Freestyle Libre System, FDA “Tentative Approval” of BI/Lilly’s insulin glargine Basaglar and NIH $20 Million commitment for Pivotal Artificial Pancreas Studies.
Metformin, a drug commonly used to treat diabetes, may raise the risk of low levels of thyroid-stimulating hormone (TSH) among patients with an underactive thyroid, a new study suggests.
The possibility of trauma inducing diabetes has been a topic of interest since Dr. Joslin was practicing medicine in the 1940s. To quote Dr. Joslin from his paper, “The Relation of Trauma to Diabetes,” published in the Annals of Surgery in 1943, “The thesis that trauma de novo can cause diabetes has steadily lost support.”
A study published in Nature this week provides evidence of a link between artificial sweeteners and diabetes, and the media is all over it. “Artificial sweeteners may disrupt body’s blood sugar controls,” wrote the New York Times; “Diet soda may alter our gut microbes and raise the risk of diabetes,” reported NPR.
sraeli Beta-O2, a company just coming out of stealth mode, announced that its ßAir bio-artificial pancreas will be put through a clinical trial thanks to a grant from the Juvenile Diabetes Research Foundation (JDRF).
This study tested the hypothesis that statin use increases the risk of diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, and gangrene of the foot in individuals with diabetes.
A paper just published in Nature bolsters that view. It provides a big dollop of evidence in support of an emerging idea that artificial sweeteners are not directly bad for people (humans cannot even digest most of them). Rather, they may be bad for the zillions of microbes that live in people’s guts—and this, in […]
Patients who use insulin pumps rather than daily insulin injections have a 29 percent reduced risk in mortality and a 43 percent reduced risk of fatal heart disease, a new study reports.
Like something straight out of HBO’s series Silicon Valley, former Allscripts CEO Glen Tullman made a splash on the TechCrunch Disrupt stage last week introducing the latest and greatest in cloud-based glucose testing tech: Livongo, with its new In Touch meter, backed by a $10 million seed investment.
Anyone who makes fitness a priority has experienced that moment when a slight tummy rumble comes along just as you head out to the gym.
This week, Wil hears a heart-breaking story about a very scary hypo and how it’s making one family wonder what options exist that could help… perhaps some diabetes tech that could be worn on the wrist? In these times of #WeAreNotWaiting, Wil has many thoughts to share on the possibilities…
A drug that mimics the action of a gut hormone combined with basal insulin is more effective at controlling blood sugar than other diabetes treatments, according to new research published in The Lancet.
Is Type 1 diabetes all in the genes? No, but genetics do play a role. The incidence of Type 1 diabetes has been increasing in children living in industrialized countries worldwide since the 1950s, on the order of 3% per year. That sort of increase cannot be explained by genetics alone.
In recent years, the medical community has become increasingly aware that taking statins can result in slightly higher glucose levels, and this can lead to a diagnosis of diabetes in a small but statistically significant number of people.
The sensor records blood glucose levels every minute, sampling the interstitial fluid using a 5mm long and .4 mm wide filament that penetrates the skin. It doesn’t require any finger prick calibration, unlike all other currently available continuous glucose monitors.
Eli Lilly and Company’s basal insulin peglispro (BIL) demonstrated a statistically significant lower hemoglobin A1c (HbA1c) compared with insulin glargine (Lantus®) at 26 weeks and 52 weeks, respectively, in the IMAGINE-1 and IMAGINE-3 Phase III clinical trials in patients with type 1 diabetes. Patients in these trials were also taking mealtime insulin.